| Members |
targetComponentId |
| Entsulfon |
Entsufon (substance) |
| Enucleation of lesion of organ NOC |
Enucleation |
| évaluation des risques environnementaux déclinée |
Environmental risk assessment declined (situation) |
| Eosinophilic leukemia |
Chronic eosinophilic leukemia (morphologic abnormality) |
| Ependymoma - category |
Ependymoma (morphologic abnormality) |
| Ependymoma, no International Classification of Diseases for Oncology subtype |
Malignant ependymoma |
| Eperythrozoon coccoides |
Mycoplasma coccoides (organism) |
| Eperythrozoon ovis |
Mycoplasma ovis (organism) |
| Eperythrozoon suis |
Mycoplasma haemosuis (organism) |
| Eperythrozoon wenyonii |
Mycoplasma wenyonii (organism) |
| Epicardial echocardiography |
Epicardial echocardiography (procedure) |
| Epidermal and animal protein specific diagnostic allergen extract |
Animal material diagnostic allergen extract (product) |
| Epidermolysis bullosa simplex with neuromuscular disease |
Epidermolysis bullosa simplex with muscular dystrophy (disorder) |
| Epidural injection of neurolytic substance, caudal |
Epidural injection of neurolytic solution, caudal |
| Epidural injection of neurolytic substance, lumbar |
Epidural injection of neurolytic solution, lumbar |
| Epilation of skin |
Epilation |
| automatisme épileptique |
Absence seizure |
| Epileptic seizure witnessed by provider of history other than subject |
Epileptic seizure witnessed by history provider (situation) |
| Epimerase |
Epimerase |
| Epinephrine 0.5% eye drops |
Adrenaline (as adrenaline acid tartrate) 500 microgram/mL eye solution |
| Epinephrine 0.5mg/mL injection solution |
Adrenaline (as adrenaline acid tartrate) 500 microgram/mL solution for injection |
| Epinephrine 1.0% solution |
Adrenaline only product |
| épinéphrine 1:10 000, 100 microgrammes/1 mL, seringue préremplie |
Product containing only epinephrine in parenteral dose form (medicinal product form) |
| Epinephrine 1:10,000 100micrograms/mL injection solution 3mL prefilled syringe |
Product containing only epinephrine in parenteral dose form (medicinal product form) |
| Epinephrine 1:1000 1mg/mL topical solution |
Adrenaline 1 mg/mL nasal solution |
| épinéphrine 1:1 000, 500 microgrammes/0,5 mL, pour injection |
Product containing only epinephrine in parenteral dose form (medicinal product form) |
| Epinephrine 2.0% solution |
Adrenaline only product |
| Epinephrine 500mcg/mL injection solution ampule |
Adrenaline (as adrenaline acid tartrate) 500 microgram/mL solution for injection |
| Epinephrine 5mcg/lidocaine hydrochloride 15mg injection solution vial |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Epinephrine 5mcg/prilocaine hydrochloride 40mg injection solution vial |
Adrenaline (as adrenaline acid tartrate) 5 microgram/mL and prilocaine hydrochloride 40 mg/mL solution for injection |
| Epinephrine acid tartrate 0.01% conventional release eye drops |
Adrenaline only product in ocular dose form |
| Epinephrine acid tartrate 0.01% preservative-free eye drops |
Adrenaline only product in ocular dose form |
| Epinephrine acid tartrate 0.1% conventional release eye drops |
Adrenaline only product in ocular dose form |
| Epinephrine acid tartrate 0.1% preservative-free eye drops |
Adrenaline only product in ocular dose form |
| Epinephrine bitartrate + pilocarpine hydrochloride 1%/1%wv solution |
Product containing only epinephrine and pilocarpine (medicinal product) |
| Epinephrine bitartrate + pilocarpine hydrochloride 1%/2%wv solution |
Product containing only epinephrine and pilocarpine (medicinal product) |
| Epinephrine bitartrate + pilocarpine hydrochloride 1%/4%wv solution |
Product containing only epinephrine and pilocarpine (medicinal product) |
| Epinephrine bitartrate + pilocarpine hydrochloride 1%/6%wv solution |
Product containing only epinephrine and pilocarpine (medicinal product) |
| Epinephrine bitartrate 5mcg/lidocaine hydrochloride 10mg injection solution vial |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Epinephrine hydrochloride 1% solution |
Adrenaline only product |
| Epinephrine hydrochloride 1.9mg dental pellet |
Adrenaline only product in dental dose form |
| Epinephrine hydrochloride 2% solution |
Adrenaline only product |
| Epineural neurolysis |
Destruction - action |
| Epiphyseal cartilage |
Structure of epiphyseal plate (body structure) |
| Epiphysiolysis |
Epiphysiodesis |
| Epiplopexy |
Omentopexy |
| Epirubicin hydrochloride 200mg/100mL solution |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Epirubicin hydrochloride 2mg/mL infusion solution 100mL vial |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Epirubicin hydrochloride 2mg/mL injection solution 100mL vial |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Episiotomy wound |
Episiotomy wound |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage I |
I |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IA |
IA |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IB |
IB |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IC |
IC |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIA |
American Joint Committee on Cancer stage IIA (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIB |
American Joint Committee on Cancer stage IIB (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage III |
American Joint Committee on Cancer stage III (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIA |
American Joint Committee on Cancer stage IIIA (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIB |
American Joint Committee on Cancer stage IIIB (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIC |
American Joint Committee on Cancer stage IIIC (qualifier value) |
| Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IV |
IV |
| Epithelial ovarian tumour, FIGO stage IVA |
American Joint Committee on Cancer stage IVA (qualifier value) |
| Epithelial ovarian tumour, FIGO stage IVB |
IVB |
| Epithelial stromal corneal dystrophy |
Epithelial basement membrane dystrophy (disorder) |
| Epithelial tumor, benign, no International Classification of Diseases for Oncology subtype |
Benign epithelial neoplasm |
| Epithelioid hemangioendothelioma |
Epithelioid hemangioendothelioma, malignant (morphologic abnormality) |
| Epoetin alfa 10000unt/mL injection |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Epoetin alfa 10000unt/mL injection solution 1mL vial |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Epoetin alfa 10000unt/mL solution |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Epoetin alfa 20000unt/mL injection solution 1mL vial |
Epoetin alfa 20000 unit/mL solution for injection |
| Epoetin alfa 2000unt/mL injection |
Epoetin alfa 2000 unit/mL solution for injection |
| Epoetin alfa 2000unt/mL injection solution 1mL vial |
Epoetin alfa 2000 unit/mL solution for injection |
| Epoetin alfa 2000unt/mL solution |
Epoetin alfa 2000 unit/mL solution for injection |
| Epoetin alfa 3000unt/mL injection solution 1mL vial |
Product containing precisely epoetin alfa 3000 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Epoetin alfa 4000unt/mL injection solution 1mL vial |
Epoetin alfa 4000 unit/mL solution for injection |
| Epoetin alfa 4000unt/mL solution |
Epoetin alfa 4000 unit/mL solution for injection |
| Epoetin beta 10,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 10,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 100,000iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 100,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 20,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 20,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 50,000iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 50,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 500iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 60,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
| Epoetin beta 60,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
| Epoophoron |
Wolffian body rest |
| syndrome d'Epstein |
MYH9 related disease |
| Eptifibatide 0.75mg injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| Eptifibatide 0.75mg/mL injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| Eptifibatide 0.75mg/mL injection solution 100mL bag |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| eptifibatide 750 microgrammes/mL, fiole de 100 mL pour perfusion |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| Equine anti-human thymocyte immunoglobulin 20mg/mL injection solution 5mL vial |
Product containing precisely equine antithymocyte immunoglobulin 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Equus asinus asinus |
Equus asinus |
| Erdheim-Chester disease |
Polyostotic sclerosing histiocytosis |
| Ergonovine maleate 200mcg/mL injection solution ampule |
Ergometrine 200 microgram/mL solution for injection |
| Ergot compound allergy |
Allergy to ergot alkaloid (finding) |
| Eribulin mesylate 0.5mg/mL conventional release solution for injection |
Product containing only eribulin in parenteral dose form (medicinal product form) |
| Eribulin mesylate 0.5mg/mL solution for intravenous infusion |
Product containing only eribulin in parenteral dose form (medicinal product form) |
| concept erroné |
Erroneous component (foundation metadata concept) |
FHIR